Targeting dormant leukaemia cells
Nature
May 12, 2008
A new role for a protein involved in leukaemia is described in Nature this week; the research demonstrates its potential as a therapeutic target to eradicate dormant leukaemia-initiating cells.
The promyelocytic leukaemia protein (PML) tumour suppressor is known to be involved in the development of some forms of leukaemia. Pier Paolo Pandolfi and colleagues identify a new and unexpected role for PML in the maintenance of both haematopoietic stem cells and leukaemia-initiating cells. They demonstrate, in mice, that targeting the protein with arsenic trioxide eliminates the cancer-initiating cells, thought to be resistant to chemotherapy and other therapies.
The team believes that their results present a new pharmacological approach to target cells that are missed by other therapies and therefore lead to disease relapse.
doi: 10.1038/nature07016
Research highlights
-
Nov 26
Evolution: Ancient bird sticks its big beak into the evolutionary recordNature
-
Nov 25
Zoology: Mineral armour discovered in insectsNature Communications
-
Nov 24
Neuroscience: Social isolation evokes craving responses in the human brainNature Neuroscience
-
Nov 20
Archaeology: Transition from tribal to feudal living in 14th century impacted local ecosystemsScientific Reports
-
Nov 18
Ecology: Migration associated with faster pace of lifeNature Communications
-
Nov 17
Gene therapy: Concerns for the long-term safety of AAV gene therapyNature Biotechnology
